Results 61 to 70 of about 177,775 (151)
Immune checkpoint inhibitors have revolutionized treatment of advanced cutaneous melanoma. This group of novel therapeutic agents differs from other systemic treatments and has necessitated a new approach for several fundamental aspects of clinical ...
Oren Levine, Tahira Devji, Feng Xie
doaj +1 more source
Pathomechanism of immune checkpoint inhibitors-induced cardiotoxicity
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that work by blocking CTLA-4, PD-1 or PD-L1 molecules. They help activate the immune system to recognize and eliminate cancer cells. Immune checkpoint inhibitors are monoclonal antibodies that
Agata Kornacka +5 more
doaj +1 more source
Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab
The clinical success of immune checkpoint inhibitors has underscored the key role of the immune system in controlling cancer. Current FDA-approved immune checkpoint inhibitors target the regulatory receptor pathways of cytotoxic T-cells to enhance their ...
Nicholas Lorig-Roach +2 more
doaj +1 more source
Tumor cells can utilize the immune checkpoint pathway to inhibit T cell activation and evade the attack of tumor specific T cells. While immune checkpoint inhibitors (ICIs) competitively bind to checkpoint molecules to block checkpoint mediated ...
Jing Chen, Xue Cheng
doaj +1 more source
Immune checkpoint inhibitor-related endocrinopathies
Lu, Difei, Gao, Ying
openaire +2 more sources
Immune Checkpoint Inhibitors in Penile Cancer
Carlo Buonerba +9 more
openaire +3 more sources
Advances in Immune Checkpoint Inhibitors for Cancer Treatment. [PDF]
Chen K, Zhu F, Li X, Yoshimura T.
europepmc +1 more source
Immune checkpoint inhibitors for invasive mucinous adenocarcinoma: A case series. [PDF]
Kato T +10 more
europepmc +1 more source
A systematic review of immune checkpoint inhibitors in endometrial cancer. [PDF]
Zhu N, Zhang C.
europepmc +1 more source
Pulmonary toxicity of immune checkpoint inhibitors. [PDF]
Garvey S, Nadarajan P.
europepmc +1 more source

